These experiments confirmed that IL-18 was a strong inducer of A2AR expression in vivo, and anti-tumor effects were even greater in A2AR knockout mice, highlighting the potential for combination therapy targeting the A2AR in conjunction with IL-18 therapy. This evidence concerns the gene IL18 and neoplasm.